Table 1. Selected examples of differential phosphorylation stoichiometry between drug sensitive (PC9) and resistance (PC9/gef.) lung cancer cell.
| Protein | p-site | p-site ratio | Motif |
Stoichiometry |
Protein ratio | ||
|---|---|---|---|---|---|---|---|
| PC9 | PC9/gef. | Difference | |||||
| HMGA1 | T53 | ND | CK2 | 6% | 42% | 36% | 0.3 |
| AP2A1 | Y418 | ND | EGFR | 11% | 34% | 23% | 1.4 |
| CDK1 | S39 | ND | CK2 | 1% | 33% | 32% | 0.7 |
| DKC1 | S453 | 2.4 | CK2 | 45% | 77% | 32% | 2.4 |
| PTPN3 | S425 | 2.4 | CK2 | 27% | 56% | 29% | 1.4 |
| KPNA3 | S60 | 2.5 | CK2 | 34% | 58% | 24% | 3.4 |
| CEBPB | T235 | 2.3 | MAPK | 41% | 62% | 21% | 1.7 |
| HNRNPK | Y280 | ND | EGFR | 0% | 20% | 20% | 0.9 |
| MET | T977 | ND | MAPK | 0% | 14% | 14% | 1.7 |
| SF3A1 | S359 | 3.5 | CK2 | 100% | 100% | 0% | 2 |
| NOP56 | S520 | 5.1 | CK2 | 63% | 61% | −2% | 2.1 |
| EGFR | Y1197 | ND | EGFR | 34% | 22% | −12% | 0.8 |
| HDAC2 | S394 | 0.1 | CK2 | 100% | 86% | −14% | 1.7 |
‘ND’ means that this phosphorylation site was not identified by conventional phosphoproteomic strategy.